Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2014: The 49th Annual Meeting of the European Association for the Study of the Liver • April 9-13, 2014 • London, United KingdomSpecial Reporting on:• SAPPHIRE II: Phase 3 Placebo-Controlled Study of Interferon-Free, 12-Week Regimen of ABT-450/R/ABT-267, ABT-333, and Ribavirin in Treatment-Experienced Adults With Hepatitis C Virus Genotype 1• All Oral Fixed-Dose Combination Sofosbuvir/Ledipasvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Naive Genotype 1 HCV-Infected Patients: the Phase 3 ION-1 Study• PEARL-III: 12 Weeks of ABT-450/R/267 + ABT-333 Achieved SVR in >99% of 419 Treatment-Naive HCV Genotype 1B-Infected Adults With or Without Ribavirin• Results of the Phase 2 Study M12-999: Interferon-Free Regimen of ABT-450/R/ABT-267 + ABT-333 + Ribavirin in Liver Transplant Recipients With Recurrent HCV Genotype 1 Infection• Sofosbuvir and Ribavirin for the Treatment of Chronic HCV With Cirrhosis and Portal Hypertension With and Without Decompensation: Early Virologic Response and Safety• All-Oral Dual Therapy With Daclatasvir and Asunaprevir in Patients With HCV Genotype 1B Infection: Phase 3 Study Results• Sofosbuvir/Ledipasvir Fixed Dose Combination Is Safe and Effective in Difficult-to-Treat Populations Including Genotype-3 Patients, Decompensated Genotype-1 Patients, and Genotype-1 Patients With Prior Sofosbuvir Treatment Experience• Sofosbuvir and Ribavirin for the Treatment of Recurrent Hepatitis C Infection After Liver Transplantation: Results of a Prospective, Multicenter StudyPLUS Meeting Abstract Summaries With Expert Commentary by: Steven L. Flamm, MDChief, Liver Transplantation ProgramProfessor of Medicine and SurgeryNorthwestern University Feinberg School of MedicineChicago, Illinois.

Literature DB >> 26180519

A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2014: The 49th Annual Meeting of the European Association for the Study of the Liver • April 9-13, 2014 • London, United KingdomSpecial Reporting on:• SAPPHIRE II: Phase 3 Placebo-Controlled Study of Interferon-Free, 12-Week Regimen of ABT-450/R/ABT-267, ABT-333, and Ribavirin in Treatment-Experienced Adults With Hepatitis C Virus Genotype 1• All Oral Fixed-Dose Combination Sofosbuvir/Ledipasvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Naive Genotype 1 HCV-Infected Patients: the Phase 3 ION-1 Study• PEARL-III: 12 Weeks of ABT-450/R/267 + ABT-333 Achieved SVR in >99% of 419 Treatment-Naive HCV Genotype 1B-Infected Adults With or Without Ribavirin• Results of the Phase 2 Study M12-999: Interferon-Free Regimen of ABT-450/R/ABT-267 + ABT-333 + Ribavirin in Liver Transplant Recipients With Recurrent HCV Genotype 1 Infection• Sofosbuvir and Ribavirin for the Treatment of Chronic HCV With Cirrhosis and Portal Hypertension With and Without Decompensation: Early Virologic Response and Safety• All-Oral Dual Therapy With Daclatasvir and Asunaprevir in Patients With HCV Genotype 1B Infection: Phase 3 Study Results• Sofosbuvir/Ledipasvir Fixed Dose Combination Is Safe and Effective in Difficult-to-Treat Populations Including Genotype-3 Patients, Decompensated Genotype-1 Patients, and Genotype-1 Patients With Prior Sofosbuvir Treatment Experience• Sofosbuvir and Ribavirin for the Treatment of Recurrent Hepatitis C Infection After Liver Transplantation: Results of a Prospective, Multicenter StudyPLUS Meeting Abstract Summaries With Expert Commentary by: Steven L. Flamm, MDChief, Liver Transplantation ProgramProfessor of Medicine and SurgeryNorthwestern University Feinberg School of MedicineChicago, Illinois.

Abstract

Entities: Chemical Disease Species

Year: 2014 PMID： 26180519 PMCID： PMC4209123

Source DB: PubMed Journal: Gastroenterol Hepatol (N Y) ISSN： 1554-7914

× No keyword cloud information.

13 in total

Review 1. Viral hepatitis in liver transplantation.

Authors: Gonzalo Crespo; Zoe Mariño; Miquel Navasa; Xavier Forns
Journal: Gastroenterology Date: 2012-05 Impact factor: 22.682

2. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.

Authors: Pietro Andreone; Massimo G Colombo; Jeffrey V Enejosa; Iftihar Koksal; Peter Ferenci; Andreas Maieron; Beat Müllhaupt; Yves Horsmans; Ola Weiland; Henk W Reesink; Lino Rodrigues; Yiran B Hu; Thomas Podsadecki; Barry Bernstein
Journal: Gastroenterology Date: 2014-05-09 Impact factor: 22.682

3. Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database.

Authors: Michael Charlton; Kris Ruppert; Steven H Belle; Nathan Bass; Daniel Schafer; Russell H Wiesner; Katherine Detre; Yuling Wei; James Everhart
Journal: Liver Transpl Date: 2004-09 Impact factor: 5.799

4. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.

Authors: Kris V Kowdley; Stuart C Gordon; K Rajender Reddy; Lorenzo Rossaro; David E Bernstein; Eric Lawitz; Mitchell L Shiffman; Eugene Schiff; Reem Ghalib; Michael Ryan; Vinod Rustgi; Mario Chojkier; Robert Herring; Adrian M Di Bisceglie; Paul J Pockros; G Mani Subramanian; Di An; Evguenia Svarovskaia; Robert H Hyland; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; David Pound; Michael W Fried
Journal: N Engl J Med Date: 2014-04-10 Impact factor: 91.245

5. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

Authors: Stefan Zeuzem; Ira M Jacobson; Tolga Baykal; Rui T Marinho; Fred Poordad; Marc Bourlière; Mark S Sulkowski; Heiner Wedemeyer; Edward Tam; Paul Desmond; Donald M Jensen; Adrian M Di Bisceglie; Peter Varunok; Tarek Hassanein; Junyuan Xiong; Tami Pilot-Matias; Barbara DaSilva-Tillmann; Lois Larsen; Thomas Podsadecki; Barry Bernstein
Journal: N Engl J Med Date: 2014-04-10 Impact factor: 91.245

6. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

Authors: Jordan J Feld; Kris V Kowdley; Eoin Coakley; Samuel Sigal; David R Nelson; Darrell Crawford; Ola Weiland; Humberto Aguilar; Junyuan Xiong; Tami Pilot-Matias; Barbara DaSilva-Tillmann; Lois Larsen; Thomas Podsadecki; Barry Bernstein
Journal: N Engl J Med Date: 2014-04-10 Impact factor: 91.245

7. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.

Authors: Fred Poordad; Christophe Hezode; Roger Trinh; Kris V Kowdley; Stefan Zeuzem; Kosh Agarwal; Mitchell L Shiffman; Heiner Wedemeyer; Thomas Berg; Eric M Yoshida; Xavier Forns; Sandra S Lovell; Barbara Da Silva-Tillmann; Christine A Collins; Andrew L Campbell; Thomas Podsadecki; Barry Bernstein
Journal: N Engl J Med Date: 2014-04-11 Impact factor: 91.245

8. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.

Authors: Eric Lawitz; Fred F Poordad; Phillip S Pang; Robert H Hyland; Xiao Ding; Hongmei Mo; William T Symonds; John G McHutchison; Fernando E Membreno
Journal: Lancet Date: 2013-11-05 Impact factor: 79.321

9. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

Authors: Nezam Afdhal; K Rajender Reddy; David R Nelson; Eric Lawitz; Stuart C Gordon; Eugene Schiff; Ronald Nahass; Reem Ghalib; Norman Gitlin; Robert Herring; Jacob Lalezari; Ziad H Younes; Paul J Pockros; Adrian M Di Bisceglie; Sanjeev Arora; G Mani Subramanian; Yanni Zhu; Hadas Dvory-Sobol; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Mark Sulkowski; Paul Kwo
Journal: N Engl J Med Date: 2014-04-11 Impact factor: 91.245

Review 10. Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectives.

Authors: Elisabetta Degasperi; Alessio Aghemo
Journal: Hepat Med Date: 2014-04-29

44 in total

1. Transitioning to highly effective therapies for the treatment of chronic hepatitis C virus infection: a policy statement and implementation guideline.

Authors: Daniel John Smyth; Duncan Webster; Lisa Barrett; Mark MacMillan; Lisa McKnight; Frank Schweiger
Journal: Can J Gastroenterol Hepatol Date: 2014-11

Review 2. Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection in 2015.

Authors: Pankaj Puri; Anil C Anand; Vivek A Saraswat; Subrat K Acharya; Radha K Dhiman; Shiv K Sarin; Shivaram P Singh; Yogesh K Chawla; Rakesh Aggarwal; Deepak Amarapurkar; Anil Arora; Vinod K Dixit; Ajit Sood; Samir Shah; Ajay Duseja; Dharmesh Kapoor; Kaushal Madan; Gaurav Pande; Aabha Nagral; Premashis Kar; Abraham Koshy; Amarender S Puri; C E Eapen; Sandeep Thareja
Journal: J Clin Exp Hepatol Date: 2015-09-21

Review 1. Viral hepatitis in liver transplantation.

2. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.

3. Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database.

4. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.

5. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

6. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

7. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.

8. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.

9. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

Review 10. Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectives.

1. Transitioning to highly effective therapies for the treatment of chronic hepatitis C virus infection: a policy statement and implementation guideline.

Review 2. Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection in 2015.

3. Dasabuvir : a new direct antiviral agent for the treatment of hepatitis C.

4. [Treatment of hepatitis C].

5. Sofosbuvir and velpatasvir: a stellar option for patients with decompensated hepatitis C virus (HCV) cirrhosis.

Review 6. Pre- and Post-Transplant Antiviral Therapy (HBV, HCV).

Review 7. Sofosbuvir for treatment of chronic hepatitis C.

Review 8. Enhancing our understanding of current therapies for hepatitis C virus (HCV).

Review 9. Hepatitis C virus infection: Are there still specific problems with genotype 3?

Review 10. Interferon-free regimens for the treatment of hepatitis C virus in liver transplant candidates or recipients.